Sarcoidosis-Like Reaction after Adjuvant Pembrolizumab in High-Risk RCC – Implications for the Urology and Oncology Communities - Beyond the Abstract
While the patient had a positive outcome, this case highlights important considerations in managing high-risk RCC patients receiving immune checkpoint inhibitors (ICIs), particularly regarding immune-related adverse events (irAEs). Pembrolizumab, a PD-1 inhibitor, has become a cornerstone in treating high-risk RCC after nephrectomy, offering significant survival benefits. However, the risk of irAEs, including granulomatous inflammation, requires careful management. Distinguishing between cancer progression and irAEs can be challenging, as immune reactions may mimic malignancy on imaging. This case underscores the need for a thorough differential diagnosis when new symptoms arise, with collaboration between oncologists, radiologists, pathologists, pulmonologists, and urologists to ensure timely diagnosis and intervention. Comprehensive diagnostic steps, including serology and cultures to rule out infections, were crucial in confirming the diagnosis. A poignant lesson from this case is the importance of listening to patients.
Despite the patient’s fatigue and respiratory symptoms, his concerns were initially dismissed as sleep apnea. As he later shared, he feared for his survival if the condition hadn’t been correctly diagnosed. This case emphasizes the need for healthcare providers to stay alert to cognitive bias and validate patient concerns to avoid overlooking rare but serious complications.
In conclusion, this case highlights the critical need for a broad differential diagnosis, a multidisciplinary approach to managing irAEs, and the importance of listening to patients. As ICIs continue to play a significant role in treating RCC and other cancers, effective collaboration and communication among specialties will be essential for optimizing patient care and outcomes.
Written by: Jue Wang, MD, FACP, Professor of Medicine, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
Read the Abstract